Perpetual Ltd Raises Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Perpetual Ltd increased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 60.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 952,172 shares of the specialty pharmaceutical company's stock after acquiring an additional 357,784 shares during the period. Jazz Pharmaceuticals comprises 1.4% of Perpetual Ltd's investment portfolio, making the stock its 19th biggest holding. Perpetual Ltd owned 1.57% of Jazz Pharmaceuticals worth $118,212,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth about $25,000. Quadrant Capital Group LLC raised its holdings in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares during the last quarter. Elequin Capital LP raised its holdings in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth about $28,000. Finally, Allianz SE acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth about $29,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on JAZZ. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Royal Bank Of Canada decreased their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $184.00.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan acquired 1,621 shares of the stock in a transaction dated Monday, May 12th. The shares were purchased at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director owned 101,621 shares in the company, valued at $10,466,963. This represents a 1.62% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 500 shares of Jazz Pharmaceuticals stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $107.90, for a total transaction of $53,950.00. Following the completion of the transaction, the chief executive officer owned 438,473 shares in the company, valued at approximately $47,311,236.70. The trade was a 0.11% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,000 shares of company stock worth $355,925. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ traded down $0.78 on Monday, hitting $106.12. The company's stock had a trading volume of 728,509 shares, compared to its average volume of 825,856. The company's 50 day simple moving average is $108.75 and its 200-day simple moving average is $119.42. The firm has a market cap of $6.42 billion, a P/E ratio of 14.15, a price-to-earnings-growth ratio of 4.61 and a beta of 0.33. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The firm had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. During the same period in the previous year, the business earned $2.68 earnings per share. The firm's revenue for the quarter was down .5% on a year-over-year basis. Analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.